Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders
Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders
复制标题
DOI：
10.1016/j.fertnstert.2017.09.008
复制
发表时间：
2017-12-01
影响因子：
6.7
通讯作者：
Polgar, Beata
中科院分区：
文献类型：
--
作者：
Brubel, Reka;Bokor, Attila;Polgar, Beata
目的：为了研究可溶性半乳糖凝集素-9（Gal-9）在子宫内膜异位症和各种妇科疾病的非侵入性实验室诊断中的有用性。设计：前瞻性病例对照研究。设置：大学医学中心。患者：共有135名育龄妇女参与研究，77名子宫内膜异位症患者，28名妇科对照和30名健康妇女。干预措施：诊断性腹腔镜检查和收集来自妇科患者和健康妇女的不同病例组的组织活检、腹膜细胞和天然外周血。主要结果测量：Gal-9的mRNA表达和血清浓度。对三个不同的患者队列进行半定量逆转录-聚合酶链反应分析和血清可溶性Gal-9 ELISA：子宫内膜异位症患者、良性妇科疾病患者和健康对照者。通过统计学评价和受试者工作特征（ROC）曲线分析确定研究组之间Gal-9浓度的差异以及血清中Gal-9的稳定性和Gal-9 ELISA的诊断特征。与健康对照组相比，在子宫内膜异位症的最小-轻度（I-II）和中度-重度（III-IV）阶段均发现Gal-9水平显著升高。在132 pg/mL的临界值下，ROC分析显示Gal-9 ELISA在子宫内膜异位症中具有极好的诊断价值（曲线下面积= 0.973），灵敏度为94%，特异性为93.75%，表明比其他子宫内膜异位症生物标志物更好的诊断潜力。此外，各种盆腔疼痛或不孕症相关的良性妇科疾病也与血清Gal-9水平升高有关。结论：我们的研究结果表明，Gal-9可能是子宫内膜异位症的一个有前途的非侵入性生物标志物和各种不孕症或盆腔疼痛相关的妇科疾病的预测。((C)2017年由美国生殖医学学会（American Society for Reproductive Medicine）
Objective: To investigate the usefulness of soluble galectin-9 (Gal-9) in the noninvasive laboratory diagnosis of endometriosis and various gynecologic disorders.Design: Prospective case-control study.Setting: University medical centers.Patient(s): A total of 135 women of reproductive age were involved in the study, 77 endometriosis patients, 28 gynecologic controls, and 30 healthy women.Intervention(s): Diagnostic laparoscopy and collection of tissue biopsies, peritoneal cells, and native peripheral blood from different case groups of gynecology patients and healthy women.Main Outcome Measure(s): The expression of mRNA and serum concentration of Gal-9.Result(s): Semiquantitative reverse transcription-polymerase chain reaction analysis and serum soluble Gal-9 ELISA were performed on three different cohorts of patients: those with endometriosis, those with benign gynecologic disorders, and healthy controls. Differences in the Gal-9 concentrations between the investigated groups and the stability of Gal-9 in the serum and diagnostic characteristics of Gal-9 ELISA were determined by statistical evaluation and receiver operating characteristic (ROC) curve analysis. Significantly elevated Gal-9 levels were found in both minimal-mild (I-II) and moderate-severe (III-IV) stages of endometriosis in comparison with healthy controls. At a cutoff of 132 pg/mL, ROC analysis revealed an excellent diagnostic value of Gal-9 ELISA in endometriosis (area under the curve = 0.973) with a sensitivity of 94% and specificity of 93.75%, indicating better diagnostic potential than that of other endometriosis biomarkers. Furthermore, various pelvic pain or infertility-associated benign gynecologic conditions were also associated with increased serum Gal-9 levels.Conclusion(s): Our results suggest that Gal-9 could be a promising noninvasive biomarker of endometriosis and a predictor of various infertility or pelvic pain-related gynecologic disorders. ((C) 2017 by American Society for Reproductive Medicine.)